Skip to main content
. 2020 Apr 21;29:0963689720919434. doi: 10.1177/0963689720919434

Fig. 3.

Fig. 3.

Comparison of costs between high and low tumor burden groups. (A) Comparison of costs between high and low tumor burdens in the ALL cohort (total cost, P < 0.001; drug cost, P < 0.001; transfusion, P < 0.001; lab test, P < 0.001; treatment cost, P < 0.001; room charge, P < 0.001; nursing, P < 0.001; radiology examination, P = 0.007; oxygen supply, P = 0.001; physician, P = 0.003; others, P < 0.001). (B) Comparison of costs between high and low tumor burdens in the NHL cohort (total cost, P > 0.05; drug cost, P > 0.05; transfusion, P > 0.05; lab test, P > 0.05; treatment cost, P > 0.05; room charge, P > 0.05; nursing, P > 0.05; radiology examination, P > 0.05; oxygen supply, P > 0.05; physician, P > 0.05; others, P > 0.05). ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin’s lymphoma.